www.fdanews.com/articles/197088-cepi-gives-novavax-384-million-in-new-funding-for-covid-19-vaccine
![MoneyinAir.gif](https://www.fdanews.com/ext/resources/test/Device_Images4/MoneyinAir.gif?t=1578528099&width=430)
CEPI Gives Novavax $384 Million in New Funding for COVID-19 Vaccine
May 13, 2020
The Coalition for Epidemic Preparedness Innovations (CEPI) is giving Novavax an additional $384 million for development of its COVID-19 vaccine.
The funding will go toward phase 1 and 2 studies, as well as the ramping up of manufacturing to produce up to 100 million doses by the end of the year. CEPI invested $4 million in the vaccine in March.
Phase 1 trials of the vaccine are expected to begin this month in Australia, with preliminary results expected in July.